These previous findings suggest that BF mediates its antitumor effects against HCC through dual inhibition of EGFR activation and subsequent attenuation of downstream RAS-RAF-MEK-ERK signaling cascade activation. The gene discussed is EGFR; the disease is hepatocellular carcinoma.